Indications and uses
Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.
Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.
2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes). NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective. 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be re...
Rx only
Nystatin is an antimycotic polyene antibiotic obtained from Streptomyces noursei. Structural formula:

Nystatin Oral Suspension, for oral administration, contains 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol (≤1% v/v), artificial wild cherry flavor, banana flavor, D&C yellow # 10, FD&C red # 40, glycerin, USP, magnesium aluminum silicate, methylparaben, NF, potassium phosphate dibasic, USP, propylene glycol, USP, propylparaben, NF, purified water, USP and sucrose 33.5%. May also contain citric acid, USP for pH adjustment.
Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.
Nystatin is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. Candida albicans demonstrates no significant resistance to nystatin in vitro on repeated subculture in increasing levels of nystatin; other Candida species become quite resistant. Generally, resistance does not develop in vivo. Nystatin acts by binding to sterols in the cell membrane of susceptible Candida species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.
Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.
The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.
This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.
No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.
Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.
It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.
Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See PRECAUTIONS: General).
Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.
Dermatologic: Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.
Other: Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.
Oral doses of nystatin in excess of five million units daily have caused nausea and gastro intestinal upset. There have been no reports of serious toxic effects of super-infections (see CLINICAL PHARMACOLOGY, Pharmacokinetics).
2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).
NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.
4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.
Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans.
Nystatin Oral Suspension, USP, 100,000 USP Nystatin Units per mL, is available as a fruit flavored, light creamy yellow, ready-to-use suspension.
NDC 68094-599-61
5 mL per unit dose cup
One Hundred (100) cups per shipper
NDC 68094-599-62
5 mL per unit dose cup
Thirty (30) cups per shipper
SHAKE CUPS WELL BEFORE USING
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing.
Rx Only
Manufactured By:
Morton Grove Pharmaceuticals, Inc.
Morton Grove, IL 60053
Manufactured For:
Wockhardt USA, LLC
Parsippany, NJ 07054
Packaged By:
Precision Dose, Inc.
South Beloit, IL 61080
For inquiries call Precision Dose, Inc. at 1-800-397-9228 or email druginfo@precisiondose.com
LI825 Rev. 06/21
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 68094-599-58 | ML - Milliliter | 68094-599 | fe4c5e77-539a-48b8-9670-2289436110c1 | 1 | 2012-07-24 |
| 68094-599-59 | ML - Milliliter | 68094-599 | 3f13beeb-08f4-487c-9f7a-7d85df700b2f | 1 | 2012-07-24 |
| 68094-599-61 | ML - Milliliter | 68094-599 | a1fc89af-e887-4bbe-ac2a-e6f648d23dc6 | 1 | 2012-07-24 |
| 68094-599-62 | ML - Milliliter | 68094-599 | 1390113c-4118-4d30-b644-756c980b9170 | 1 | 2012-07-24 |
| 60432-537-16 | ML - Milliliter | 60432-537 | 4cade063-c2f1-481b-8ce0-2f183b5989df | 1 | 2012-07-24 |
| 60432-537-60 | ML - Milliliter | 60432-537 | a627d2f6-c5a2-4e15-80fc-69e008e6482b | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Nystatin | ACTIVE INGREDIENT | BDF1O1C72E | 2 | |
| Nystatin | ACTIVE MOIETY | BDF1O1C72E | 2 | |
| alcohol | INACTIVE INGREDIENT | 3K9958V90M | 2 | |
| D&C yellow no. 10 | INACTIVE INGREDIENT | 35SW5USQ3G | 2 | |
| FD&C red no. 40 | INACTIVE INGREDIENT | WZB9127XOA | 2 | |
| glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 2 | |
| magnesium aluminum silicate | INACTIVE INGREDIENT | 6M3P64V0NC | 2 | |
| methylparaben | INACTIVE INGREDIENT | A2I8C7HI9T | 2 | |
| potassium phosphate, dibasic | INACTIVE INGREDIENT | CI71S98N1Z | 2 | |
| propylene glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | 2 | |
| propylparaben | INACTIVE INGREDIENT | Z8IX2SC1OH | 2 | |
| sucrose | INACTIVE INGREDIENT | C151H8M554 | 2 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 68094-599 | 68094-599-59, 68094-599-62, 68094-599-61, 68094-599-58 |
| 60432-537 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Nystatin | BDF1O1C72E | ACTIB |
| alcohol | 3K9958V90M | IACT |
| D&C yellow no. 10 | 35SW5USQ3G | IACT |
| FD&C red no. 40 | WZB9127XOA | IACT |
| glycerin | PDC6A3C0OX | IACT |
| magnesium aluminum silicate | 6M3P64V0NC | IACT |
| methylparaben | A2I8C7HI9T | IACT |
| DIBASIC POTASSIUM PHOSPHATE | CI71S98N1Z | IACT |
| propylene glycol | 6DC9Q167V3 | IACT |
| propylparaben | Z8IX2SC1OH | IACT |
| water | 059QF0KO0R | IACT |
| sucrose | C151H8M554 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / RESPIRATORY (INHALATION) | 0.01 %w/w | ||
| sucrose | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| D&C yellow no. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | GEL / DENTAL | NA | ||
| alcohol | ALCOHOL | 3K9958V90M | AEROSOL, METERED / RESPIRATORY (INHALATION) | 26664 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / OPHTHALMIC | 1 %w/v | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / PARENTERAL | 30 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / TOPICAL | 5148 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / NASAL | 5 mg | ||
| alcohol | ALCOHOL | 3K9958V90M | INJECTION / INTRAMUSCULAR | 1491 mg | ||
| FD&C red no. 40 | FD&C RED NO. 40 | WZB9127XOA | CONCENTRATE / ORAL | 0.04 mg/1ml | ||
| FD&C red no. 40 | FD&C RED NO. 40 | WZB9127XOA | CAPSULE, LIQUID FILLED / ORAL | 1 mg | ||
| D&C yellow no. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | SYRUP / ORAL | 4 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | CREAM / VAGINAL | 22 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | DROPS / ORAL | 1 mg/1ml | ||
| sucrose | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| D&C yellow no. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | TABLET / ORAL | 80 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / ORAL | 388 mg | ||
| sucrose | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | FILM, SOLUBLE / BUCCAL | 1 mg | ||
| magnesium aluminum silicate | MAGNESIUM ALUMINUM SILICATE | 6M3P64V0NC | OINTMENT / VAGINAL | 231 mg | ||
| alcohol | ALCOHOL | 3K9958V90M | CONCENTRATE / ORAL | 198 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | JELLY / TOPICAL | 420 mg | ||
| D&C yellow no. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | CAPSULE, DELAYED RELEASE / ORAL | 1 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SPONGE / TOPICAL | 2 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | GUM, CHEWING / BUCCAL | 230 mg | ||
| D&C yellow no. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | CAPSULE, COATED PELLETS / ORAL | 0.01 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | CAPSULE, EXTENDED RELEASE / ORAL | 2 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION / AURICULAR (OTIC) | 0.05 %w/w | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM / BUCCAL | 1.48 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / AURICULAR (OTIC) | 56.55 %w/v | ||
| alcohol | ALCOHOL | 3K9958V90M | SOLUTION, CONCENTRATE / ORAL | 150.68 mg/1ml | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / INTRAMUSCULAR | 7459 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | CREAM / TOPICAL | 76000 mg | ||
| sucrose | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| magnesium aluminum silicate | MAGNESIUM ALUMINUM SILICATE | 6M3P64V0NC | LIQUID / ORAL | 82 mg/5ml | ||
| glycerin | GLYCERIN | PDC6A3C0OX | TABLET / PERIODONTAL | 0.53 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | AEROSOL, FOAM / TOPICAL | 21 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | INJECTION / PARENTERAL | 18 mg | ||
| potassium phosphate, dibasic | DIBASIC POTASSIUM PHOSPHATE | CI71S98N1Z | SOLUTION / ORAL | 890 mg | ||
| D&C yellow no. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | POWDER, FOR SUSPENSION / ORAL | 76 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / RESPIRATORY (INHALATION) | 25 %w/w | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / TOPICAL | 5.28 %w/v | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SUSPENSION / INTRAMUSCULAR | 0.02 %w/v | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SUPPOSITORY / VAGINAL | NA | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION / INTRAVENOUS | 0.13 %w/v | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION, CONCENTRATE / ORAL | 2590 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRALESIONAL | 0.02 %w/v | ||
| FD&C red no. 40 | FD&C RED NO. 40 | WZB9127XOA | CAPSULE, EXTENDED RELEASE / ORAL | 1 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / TOPICAL | 4974 mg | ||
| alcohol | ALCOHOL | 3K9958V90M | SPRAY / TOPICAL | 3633 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION / INTRAMUSCULAR | 0.13 %w/v | ||
| sucrose | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, COATED / ORAL | 25 mg | ||
| D&C yellow no. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | POWDER, FOR SOLUTION / ORAL | NA | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | GEL / OPHTHALMIC | 0.88 %w/w | ||
| sucrose | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / SUBCUTANEOUS | 0.16 %w/v |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A062512-001 | NYSTATIN | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 |
| Application-product | TE code |
|---|---|
| A062512-001 | AA |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1984-10-29 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A062512-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | RS | 1984-10-29 | 3bdfa0b2c4d7… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A062512-001 | AA | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A062512-001 | AA | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A062512-001 | AA | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A062512-001 | AA | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A062512-001 | AA | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062512-001 | AA | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A062512-001 | AA | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A062512-001 | AA | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A062512-001 | AA | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A062512-001 | AA | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A062512-001 | AA | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A062512-001 | AA | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A062512-001 | AA | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A062512-001 | AA | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A062512-001 | AA | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A062512-001 | AA | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A062512-001 | AA | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A062512-001 | AA | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A062512-001 | AA | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A062512-001 | AA | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A062512-001 | AA | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A062512-001 | AA | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A062512-001 | AA | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A062512-001 | AA | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A062512-001 | AA | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A062512-001 | AA | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A062512-001 | AA | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A062512-001 | AA | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A062512-001 | AA | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A062512-001 | AA | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A062512-001 | AA | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A062512-001 | AA | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A062512-001 | AA | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A062512-001 | AA | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A062512-001 | AA | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A062512-001 | AA | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A062512-001 | AA | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A062512-001 | AA | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A062512-001 | AA | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A062512-001 | AA | 1 | 3bdfa0b2c4d7… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 86bf7f7b-cb8b-4592-98f3-c8733cd080f9 | 29a5391d-6db4-4226-82ed-4481b3e445c8 | 2023-01-25 | Adverse reactions | 86bf7f7b-cb8b-4592-98f3-c8733cd080f9 29a5391d-6db4-4226-82ed-4481b3e445c8 |
Adverse event summaries are temporarily unavailable. Other product information remains available.